These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 10896408

  • 1. Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians.
    Simooya OO, Sijumbil G, Lennard MS, Tucker GT.
    Br J Clin Pharmacol; 1998 Mar; 45(3):315-7. PubMed ID: 10896408
    [Abstract] [Full Text] [Related]

  • 2. 3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.
    Zhen Y, Slanar O, Krausz KW, Chen C, Slavík J, McPhail KL, Zabriskie TM, Perlík F, Gonzalez FJ, Idle JR.
    Drug Metab Dispos; 2006 Sep; 34(9):1563-74. PubMed ID: 16782768
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes.
    Dalén P, Dahl M, Andersson K, Bertilsson L.
    Br J Clin Pharmacol; 2000 Feb; 49(2):180-4. PubMed ID: 10671914
    [Abstract] [Full Text] [Related]

  • 4. Lack of effect of chloroquine on the debrisoquine (CYP2D6 and S-mephenytoin (CYP2C19) hydroxylation phenotypes.
    Masimirembwa CM, Gustafsson LL, Dahl ML, Abdi YA, Hasler JA.
    Br J Clin Pharmacol; 1996 Apr; 41(4):344-6. PubMed ID: 8730982
    [Abstract] [Full Text] [Related]

  • 5. Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo.
    Wennerholm A, Nordmark A, Pihlsgård M, Mahindi M, Bertilsson L, Gustafsson LL.
    Eur J Clin Pharmacol; 2006 Jul; 62(7):539-46. PubMed ID: 16783563
    [Abstract] [Full Text] [Related]

  • 6. Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship.
    Dorado P, Berecz R, Cáceres MC, González I, Cobaleda J, Llerena A.
    Clin Chem Lab Med; 2005 Jul; 43(3):275-9. PubMed ID: 15843230
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The effect of a long term epidural infusion of ropivacaine on CYP2D6 activity.
    Wink J, Veering BT, Kruit M, Burm AG, Huledal GA, Ekström GY, Stienstra R, van Kleef JW.
    Anesth Analg; 2008 Jan; 106(1):143-6, table of contents. PubMed ID: 18165569
    [Abstract] [Full Text] [Related]

  • 9. An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems.
    Halliday RC, Jones BC, Smith DA, Kitteringham NR, Park BK.
    Br J Clin Pharmacol; 1995 Oct; 40(4):369-78. PubMed ID: 8554939
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
    Laine K, Tybring G, Härtter S, Andersson K, Svensson JO, Widén J, Bertilsson L.
    Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
    [Abstract] [Full Text] [Related]

  • 12. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.
    Wanwimolruk S, Bhawan S, Coville PF, Chalcroft SC.
    Eur J Clin Pharmacol; 1998 Jul; 54(5):431-5. PubMed ID: 9754989
    [Abstract] [Full Text] [Related]

  • 13. Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs.
    Masimirembwa C, Hasler J, Bertilssons L, Johansson I, Ekberg O, Ingelman-Sundberg M.
    Eur J Clin Pharmacol; 1996 Jul; 51(2):117-22. PubMed ID: 8911874
    [Abstract] [Full Text] [Related]

  • 14. A micromethod for quantitation of debrisoquine and 4-hydroxydebrisoquine in urine by liquid chromatography.
    Pereira VA, Auler JO, Carmona MJ, Mateus FH, Lanchote VL, Breimer DD, Santos SR.
    Braz J Med Biol Res; 2000 May; 33(5):509-14. PubMed ID: 10775881
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. In vitro activity of halofantrine and its relationship to other standard antimalarial drugs against African isolates and clones of Plasmodium falciparum.
    Basco LK, Le Bras J.
    Am J Trop Med Hyg; 1992 Oct; 47(4):521-7. PubMed ID: 1443351
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians.
    Dalén P, Dahl ML, Roh HK, Tybring G, Eichelbaum M, Wilkinson GR, Bertilsson L.
    Br J Clin Pharmacol; 2003 Jun; 55(6):630-4. PubMed ID: 12814461
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.